13 research outputs found
In vivo monitoring of dynamic interaction between neutrophil and human umbilical cord blood-derived mesenchymal stem cell in mouse liver during sepsis
BACKGROUND:
Sepsis is a global inflammatory disease that causes death. It has been reported that mesenchymal stem cell (MSC) treatment can attenuate inflammatory and septic symptoms. In this study, we investigated how interactions between neutrophils and human umbilical cord blood (hUCB)-MSCs in the liver of septic mice are involved in mitigating sepsis that is mediated by MSCs. Accordingly, we aimed to determine whether hUCB-MSC application could be an appropriate treatment for sepsis.
METHODS:
To induce septic condition, lipopolysaccharide (LPS) was intraperitoneally (i.p.) injected into mice 24βh after the intravenous (i.v.) injection of saline or hUCB-MSCs. To determine the effect of hUCB-MSCs on the immune response during sepsis, histologic analysis, immunoassays, and two-photon intravital imaging were performed 6βh post-LPS injection. For the survival study, mice were monitored for 6βdays after LPS injection.
RESULTS:
The injection (i.v.) of hUCB-MSCs alleviated the severity of LPS-induced sepsis by increasing IL-10 levels (pβ<β0.001) and decreasing mortality (pβ<β0.05) in septic mice. In addition, this significantly reduced the recruitment of neutrophils (pβ<β0.001) to the liver. In hUCB-MSC-treated condition, we also observed several distinct patterns of dynamic interactions between neutrophils and hUCB-MSCs in the inflamed mouse liver, as well as vigorous interactions between hepatic stellate cells (HSCs or ito cells) and hUCB-MSCs. Interestingly, hUCB-MSCs that originated from humans were not recognized as foreign in the mouse body and consequently did not cause graft rejection.
CONCLUSIONS:
These distinct interaction patterns between innate immune cells and hUCB-MSCs demonstrated that hUCB-MSCs have beneficial effects against LPS-induced sepsis through associations with neutrophils. In addition, the immunomodulatory properties of hUCB-MSCs might enable immune evasion in the host. Taken together, our results suggest the prospects of hUCB-MSCs as a therapeutic tool to inhibit inflammation and alleviate pathological immune responses such as sepsis.ope
Conserved Noncoding Sequences Boost ADR1 and SP1 Regulated Human Swiprosin-1 Promoter Activity
Swiprosin-1 is expressed in various types of cells or tissues of different species. To investigate the mechanisms underlying Swiprosin-1 expression pattern, we analyzed the promoter activity of 2-kilobase genomic sequences located at 5' flanking region of the Swiprosin-1 gene. The -2000/+41βbp of 5' flanking untranslated promoter region of Swiprosin-1 gene was constitutively transactivated without significant effect of PMA, A23187, or PMA/A23187 stimulation in Jurkat T cells. Further, we identified 5' deletant of proximal promoter region (-100/+41 to -70/+41) plays a pivotal role in activating the Swiprosin-1 gene in Jurkat T cells. Our studies also verified that ADR1 and Sp1 transcription factors were located between -70 and -100 locus of 5' flanking proximal promoter region, which is critical for the Swiprosin-1 promoter activity. ADR1 and Sp1 were shown to bind the regions of -82, -79, -76, -73 and -70 and; -79, -78 and -77, respectively, within the proximal promoter region of Swiprosin-1. Finally conserved noncoding sequences (CNS) -1, -2 and -3 were located between the exon 1 and exon 2 of Swiprosin-1 gene and synergistically transactivated the Swiprosin-1 promoter. In summary, Swiprosin-1 was constitutively expressed in Jurkat T cells by the coordinate action of ADR1 and SP1 transcription factors at the transcriptional level and CNS further boost the proximal region of Swiprosin-1 promoter activity. Our findings provide novel insights that the transcriptional regulation of Swiprosin-1 by targeting ADR1 and Sp1 binding sites may be helpful in exploring novel therapeutic strategies for advanced immune or other disorders.ope
Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3
Despite the importance of Ras oncogenes as a therapeutic target in human cancer, their 'undruggable' tertiary structures limit the effectiveness of anti-Ras drugs. Canonical Wnt signaling contributes to Ras activity by glycogen synthase kinase 3 (GSK-3)-dependent phosphorylation at the C-terminus and subsequent degradation. In the accompanying report, we show that the anti-helminthic niclosamide directly binds to GSK-3 and inhibits Axin functions in colon cancer cells, with reversion of Snail-mediated epithelial-mesenchymal transition. In this study, we report that niclosamide effectively suppresses Ras and nuclear NFAT activities regardless of the mutational status of Ras at nM levels. Mechanistically, niclosamide increased endogenous GSK-3 activity, shortening the half-life of mutant Ras. Further, niclosamide activates Raf-1 kinase inhibitory protein, a downstream target of Snail repressor. Niclosamide treatment attenuates Ras-induced oncogenic potential in vitro and in vivo. These findings provide a clinically available repositioned Ras inhibitor as well as a novel strategy for inhibiting the Ras via GSK-3.ope
Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction
The epithelial-mesenchymal transition (EMT) is implicated in tumorigenesis and cancer progression, and canonical Wnt signaling tightly controls Snail, a key transcriptional repressor of EMT. While the suppression of canonical Wnt signaling and EMT comprises an attractive therapeutic strategy, molecular targets for small molecules reverting Wnt and EMT have not been widely studied. Meanwhile, the anti-helminthic niclosamide has been identified as a potent inhibitor of many oncogenic signaling pathways although its molecular targets have not yet been clearly identified. In this study, we show that niclosamide directly targets Axin-GSK3 interaction, at least in part, resulting in suppression of Wnt/Snail-mediated EMT. In vitro and in vivo, disruption of Axin-GSK3 complex by niclosamide induces mesenchymal to epithelial reversion at nM concentrations, accompanied with suppression of the tumorigenic potential of colon cancer. Niclosamide treatment successfully attenuates Snail abundance while increasing E-cadherin abundance in xenograft tumor. Notably, oral administration of niclosamide significantly suppressed adenoma formation in an APC-MIN mice model, indicating that niclosamide is an effective therapeutic for familial adenomatosis polyposis (FAP) patients. In this study, we identified a novel target to control the canonical Wnt pathway and Snail-mediated EMT program, and discovered a repositioned therapeutics for FAP patients.ope
A Study on Improving the Performance of Demand Paging for NAND Flash based Embedded Systems
λ³Έ λ
Όλ¬Έμ λΈλ νλμ λ©λͺ¨λ¦¬ κΈ°λ°μ λ맨λ νμ΄μ§ μμ€ν
μμ νμ΄μ§ ν΄νΈμ μ²λ¦¬ μ±λ₯μ ν₯μμν€κΈ° μν κΈ°λ²μ λν΄ λ
Όμνμλ€. νΉν μλΈλ νλμ λ©λͺ¨λ¦¬λ₯Ό μ¬μ©νλ λ΄μ₯ν μμ€ν
μμ μ
μΆλ ₯ μν€ν
μ² κ°μ μ ν΅ν΄ λ맨λ νμ΄μ§ μ±λ₯μ κ°μ ν μ μλ κΈ°λ²κ³Ό μμΆνμΌμμ€ν
νκ²½μμ μμΆν΄μ μ€λ²ν€λλ₯Ό μ€μμΌλ‘μ¨ λ맨λ νμ΄μ§ μ±λ₯μ ν₯μμν¬ μ μλ κΈ°λ²λ€μ μ μνλ€.
μλΈλ νλμ λ©λͺ¨λ¦¬λ κΈ°μ‘΄ λΈλ νλμ λ©λͺ¨λ¦¬μ μ±λ₯μ 보μν ν¨μ λ©λͺ¨λ¦¬λ‘ νΉν ν° μ½κΈ° μμ²μ λΉ λ₯΄κ² μ²λ¦¬ν μ μλ€. νμ§λ§ νμ¬ μ΄μ체μ μ μ
μΆλ ₯ μν€ν
μ²μμλ νμ΄μ§ ν΄νΈλ‘ μΈν΄ λ°μνλ ν° μ½κΈ° μμ²μ΄ μ
μΆλ ₯ μΈκ·Έλ¨ΌνΈ λ¨μλ‘ λ¨νΈν λκΈ° λλ¬Έμ μλΈλ νλμ λ©λͺ¨λ¦¬μ μ±λ₯μ μ λλ‘ νμ©ν μκ° μλ€.
λ³Έ λ
Όλ¬Έμμλ μ΄λ₯Ό ν΄κ²°νκΈ° μν΄ λ€μ λ κ°μ§ κΈ°λ²μ μ μνλ€. 첫 λ²μ§Έ, κ°μ μ
μΆλ ₯ μΈκ·Έλ¨ΌνΈ κΈ°λ²μ μ¬λ¬ κ°μ μ
μΆλ ₯ μΈκ·Έλ¨ΌνΈλ₯Ό κ°μ μ£Όμ 맀νμ ν΅ν΄ νλμ ν° κ°μ μ
μΆλ ₯ μΈκ·Έλ¨ΌνΈλ‘ μ²λ¦¬ν¨μΌλ‘μ¨ κΈ°μ‘΄ νμ΄μ§ ν΄νΈ μ²λ¦¬ μκ°μ μ½ 48%κ°λ μ€μΌ μ μμλ€. λ λ²μ§Έ, λ²‘ν° μ½κΈ° κΈ°λ²μ κ°μ μ
μΆλ ₯ μΈκ·Έλ¨ΌνΈ κΈ°λ²μ λ¨μ μΈ μμ μ½κΈ° μ±λ₯μ ν₯μμν€λ κΈ°λ²μΌλ‘ μΈν°νμ΄μ€μ λ³κ²½ λ° κ°μ μ ν΅ν΄ λλ°μ΄μ€μμμ λΉμ°μμ μΈ μ½κΈ° μμ²λ€μ νλ²μ μλΈλ νλμ λ©λͺ¨λ¦¬μ μ λ¬νλ κΈ°λ²μ΄λ€. μ±λ₯νκ° κ²°κ³Όμ λ°λ₯΄λ©΄ λ²‘ν° μ½κΈ° κΈ°λ²μ μ¬μ©ν κ²½μ° νμ΄μ§ ν΄νΈ μ²λ¦¬ μκ°μ 56.5%κΉμ§ κ°μμν¬ μ μμλ€.
μμΆνμΌμμ€ν
μ μ½κΈ° μ±λ₯ κ°μ μ μν΄μλ λ€μ λ κ°μ§ κΈ°λ²μ΄ μ μλμλ€. 첫 λ²μ§Έλ 미리μ½κΈ°λ₯Ό κ³ λ €ν μμΆνμΌμμ€ν
μ΄λ€. 미리μ½κΈ° κΈ°λ²μ μΌλ°μ μΌλ‘ λ맨λ νμ΄μ§ μμ€ν
μ μ±λ₯μ ν₯μμν€μ§λ§ μμΆ νμΌμμ€ν
μ κ²½μ°μλ μ€νλ € λΆνμν μμΆν΄μ μ€λ²ν€λλ₯Ό λ°μμμΌ νμ΄μ§ ν΄νΈ μ²λ¦¬ μκ°μ ν¬κ² μ¦κ°μν¨λ€. μ΄λ₯Ό ν΄κ²°νκΈ° μν΄ λ³Έ λ
Όλ¬Έμμλ μ νμ μμΆν΄μ λ₯Ό ν΅ν΄ λΆνμν μμΆν΄μ μ€λ²ν€λλ₯Ό μ κ±°νλ κΈ°λ²μ μ μνλ€. μ±λ₯νκ°μ λ°λ₯΄λ©΄ μ μλ κΈ°λ²μ μμΆνμΌμμ€ν
μ νμ΄μ§ ν΄νΈ μ²λ¦¬ μκ°μ 28%κΉμ§ μ€μΌ μ μμλ€. λ λ²μ§Έλ κ°μμ£Όμ 맀νμ μ΄μ©ν΄ SquahFSμ μ½κΈ°μ±λ₯μ μ΅μ νμν€λ κΈ°λ²μ΄λ€. SquashFSλ μμΆλ₯ μ΄ λκ³ μμ μ±μ΄ λ°μ΄λ μμΆνμΌμμ€ν
μ΄μ§λ§ μμΆν΄μ κ³Όμ μ΄ λΉν¨μ¨μ μ΄λ€. λ³Έ λ
Όλ¬Έμμλ κ°μ μ£Όμ 맀νμ μ΄μ©ν΄ λ°λ³΅μ μΈ μμΆν΄μ ν¨μ νΈμΆκ³Ό λΆνμν λ³΅μ¬ μ€λ²ν€λλ₯Ό μ κ±°ν΄ SquashFSμ μμΆν΄μ κ³Όμ μ μ΅μ ν μμΌ°λ€. μ±λ₯νκ°μ λ°λ₯΄λ©΄ μ μλ μ΅μ ν κΈ°λ²μ SquashFSμ μ½κΈ° μ±λ₯μ 20%κΉμ§ ν₯μμν¬ μ μμλ€.Docto
The Role of MSCs in the Tumor Microenvironment and Tumor Progression
Over the past few decades, longevity without disease has become an important topic worldwide. However, as life expectancy increases, the number of patients with cancer is also increasing. Tumor progression is related to interactions between tumor cells and mesenchymal stem cells (MSCs) in the tumor microenvironment. MSCs are multipotent stromal cells known to be present in a variety of locations in the body, including bones, cartilage, fat, muscles, and dental pulp. MSCs migrate toward inflamed areas during pathological immune responses. MSCs also migrate toward tumor stroma and participate in tumor progression. MSCs can contribute to tumor progression by interacting with tumor cells via paracrine signaling and differentiate into diverse cell types. This also enables MSCs to make direct contact with tumor cells in tumor stroma. Interactions between tumor cells and MSCs enhance tumorigenic and metastatic potential, in addition to stimulating epithelial to mesenchymal transition. Herein, we reviewed the research associated with the tumor-enhancing role of MSCs in tumor progression, from primary tumor growth to distant tumor metastasis.restrictio
μνμ λ₯Ό λμμΌλ‘ ν μκ°ν¬μμ₯μΉμ κ°λ°
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :λ곡νκ³Ό λμ
κΈ°κ³μ 곡,1999.Maste
ν΄λ¦¬μΌνλΉλTiOβ λλ Ένμ΄λΈλ¦¬λλ₯Ό μ΄μ©ν λ€μ΄μ₯μ λ°°μΆ μ΅μ μ κ΄ν μ°κ΅¬
Thesis(master`s)--μμΈλνκ΅ λνμ :μ¬λ£κ³΅νλΆ,2005.Maste